The immunological role of ADAMs in the field of gastroenterological chronic inflammatory diseases and cancers: a review
Autor: | Jun Arai, Yumi Otoyama, Hisako Nozawa, Naoya Kato, Hitoshi Yoshida |
---|---|
Rok vydání: | 2022 |
Předmět: | |
Zdroj: | Oncogene. 42:549-558 |
ISSN: | 1476-5594 0950-9232 |
Popis: | Metalloproteinases cleave transmembrane proteins that play critical roles in inflammation and cancers. Metalloproteinases include a disintegrin and metalloprotease (ADAM), which we previously examined using a fluorescence assay system, and described their association with resistance to systemic therapy in cancer patients. There are also many reports on the relation between ADAM expression and the prognosis of patients with gastroenterological chronic inflammatory diseases and cancers. Inhibiting their immunomodulating activity in chronic inflammation restores innate immunity and potentially prevents the development of various cancers. Among the numerous critical immune system-related molecules, we focus on major histocompatibility complex class I polypeptide-related sequence A (MICA), MICB, intracellular adhesion molecule (ICAM)-1, TNF-α, IL-6 receptor (IL-6R), and Notch. This review summarizes our current understanding of the role of ADAMs in gastroenterological diseases with regard to the immune system. Several Food and Drug Administration (FDA)-approved inhibitors of ADAMs have been identified, and potential therapies for targeting ADAMs in the treatment of chronic inflammatory diseases and cancers are discussed. Some ongoing clinical trials for cancers targeting ADAMs are also introduced. |
Databáze: | OpenAIRE |
Externí odkaz: |